Skip to main content
NCBI home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1993 Jan;36(1):18–24. doi: 10.1007/BF01789126

Effect of cisplatin upon expression of in vivo immune tumor resistance

Edward D Crum 1,✉
PMCID: PMC11038654  PMID: 8422664

Abstract

The major intent of cancer treatment with cytotoxic drugs is direct tumor cell damage, but some of these drugs have been shown to be immunomodulatory. Cisplatin is a widely used cytotoxic drug that has been combined with biological response modifiers in recent clinical trials. To evaluate further whether cisplatin may independently alter the level of host resistance against tumor growth, the drug was tested in the Mc7 sarcoma rat tumor model. The expression of in vivo tumor resistance against Mc7 sarcoma in syngeneic Wistar rats is mediated by circulating non-cytotoxic T lymphocytes. These cells interact specifically with tumor cells to generate cytotoxic effectors locally at the site of a tumor challenge. Activities of these components of expression of tumor resistance were measured in vivo after administration of cisplatin and dose-dependent effects were found. Low-dose cisplatin (0.3 mg/kg) increased the activity of the circulating lymphocytes that mediate tumor resistance, and high-dose cisplatin (9 mg/kg) suppressed both mediator lymphocyte activity and the generation of antitumor effector mechanisms. These studies suggest that low-dose cisplatin may be immunomodulatory and combining it with biological response modifiers might be a useful strategy. However, high-dose cisplatin given with biological response modifiers may negate potential immunomodulatory activities of such agents.

Key words: Tumor immunity, Tumor resistance, Immunomodulation, Cisplatin

References

  • 1.Awwad M, North RJ. Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of Cy-resistant tumor. Evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing T-cells rather than reducing tumor burden. Immunology. 1988;65:87. [PMC free article] [PubMed] [Google Scholar]
  • 2.Awwad M, North RJ. Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant tumor murine tumor: a consequence of eliminating precursor L3T4+ suppressor T-cells. Cancer Res. 1989;49:1649. [PubMed] [Google Scholar]
  • 3.Baldwin RW, Pimm MV. BCG immunotherapy of a rat sarcoma. Br J Cancer. 1973;28:2812. doi: 10.1038/bjc.1973.149. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Bartik MM, Takesue BY, Mokyr MB. Melphalan-induced enhancement of antitumor immune reactivity in thymocytes of adult BALB/c mice bearing a large MOPC-315 tumor. Cancer Res. 1987;47:4848. [PubMed] [Google Scholar]
  • 5.Boyne P, Robinson BA, Murphy P, McKay M. Enzymatic correction of interference in the kinetic Jaffe reaction for determining creatinine in plasma. Clin Chem. 1985;31:1564. [PubMed] [Google Scholar]
  • 6.Crum ED. lymphocytes that mediate systemic resistance to in vivo growth of a carcinogen-induced syngeneic tumor. Int J Cancer. 1980;26:53. doi: 10.1002/ijc.2910260109. [DOI] [PubMed] [Google Scholar]
  • 7.Crum ED. Subsets of circulating T-lymphocytes mediating resistance to in vivo growth of a carcinogen-induced syngeneic rat tumor. Cancer Res. 1984;44:3196. [PubMed] [Google Scholar]
  • 8.Crum ED. Specific induction of local antitumor effector cells mediated in vivo by the circulating lymphocyte pool. Cancer Res. 1987;47:5584. [PubMed] [Google Scholar]
  • 9.DeConti RC, Toftness BR, Lange RC, Creasy WA. Clinical and pharmacological studies withcis-diamminedichloroplatinum (II) Cancer Res. 1972;33:1310. [PubMed] [Google Scholar]
  • 10.Ehrke MJ, Mihich E, Berd D, Mastrangelo MJ. Effects of anticancer drugs on the immune system in humans. Semin Oncol. 1989;16:230. [PubMed] [Google Scholar]
  • 11.Gormley PE, Bull JM, LeRoy AF, Cysyk R. Kinetics ofcis-dichlorodiammineplatinum. Clin Pharmocol Ther. 1977;25:351. doi: 10.1002/cpt1979253351. [DOI] [PubMed] [Google Scholar]
  • 12.Hillgard P, Pohl J, Stekar J, Voegeli R. Oxazaphosphorines as biological response modifiers; experimental and clinical perspectives. Cancer Treat Rev. 1984;12:155. doi: 10.1016/0305-7372(85)90036-2. [DOI] [PubMed] [Google Scholar]
  • 13.Kleinerman ES, Zwelling LA, Muchmore AV. Enhancement of naturally occuring human spontaneous monocyte-mediated cytotoxicity bycis-diamminedichloro-platinum(II) Cancer Res. 1980;40:3099. [PubMed] [Google Scholar]
  • 14.Kociba RJ, Sleight SD. Acute toxicologic and pathologic effects of cis-diamminedichloroplatinum (NSC-119 875) in the male rat. Cancer Chemother Rep. 1971;55:1. [PubMed] [Google Scholar]
  • 15.Lichtenstein AK, Pende D. Enhancement of natural killer cytotoxicity bycis-diamminedichloroplatinum (II) in vivo and in vitro. Cancer Res. 1986;46:639. [PubMed] [Google Scholar]
  • 16.Litterst CL, Torres IJ, Guarino AM. Plasma levels and organ distribution of platinum in the rat, dog, and dogfish shark following single intravenous administration ofcis-dichlorodiammine-platinum (II) J Clin Hematol Oncol. 1977;7:169. [Google Scholar]
  • 17.Margolin K, Doroshow J, Akman S, et al. Treatment of advanced melanoma with cisplatin and alpha interferon. Proc Am Assoc Clin Oncol. 1990;9:277. [Google Scholar]
  • 18.Mathe G, Halle-Pannenko O, Bourut C. Effectiveness of murine leukemia chemotherapy according to the immune state. Cancer Immunol Immunother. 1977;2:139. doi: 10.1007/978-3-642-81174-6_3. [DOI] [PubMed] [Google Scholar]
  • 19.Mitchell MS. Combining chemotherapy with biological response modifiers in the treatment of cancer. J Natl Cancer Inst. 1988;80:1445. doi: 10.1093/jnci/80.18.1445. [DOI] [PubMed] [Google Scholar]
  • 20.Nagarkatti M, Toney DM, Nagarkatti PS. Immunomodulation by various nitrosoureas and its effect on the survival of the murine host bearing a syngeneic tumor. Cancer Res. 1989;49:6587. [PubMed] [Google Scholar]
  • 21.North RJ. Down-regulation of the antitumor immune response. Adv Cancer Res. 1985;45:1. doi: 10.1016/s0065-230x(08)60265-1. [DOI] [PubMed] [Google Scholar]
  • 22.Patton TF, Himmelstein KJ, Belt R, et al. Plasma levels and urinary excretion of filterable platinum species following bolus injection and i.v. infusion ofcis-dichlorodiammineplatinum (II) in man. Cancer Treat Rep. 1978;9:1359. [PubMed] [Google Scholar]
  • 23.Piel IJ, Rayadu GVS, Perlia CP, et al. Use of neutron activation analysis to study excretion ofcis-diamminedichloroplatinum (DDP) in cancer patients. Proc Am Assoc Cancer Res. 1974;15:111. [Google Scholar]
  • 24.Pross HF, Baines MG, Rubin P, Shragge P, Patterson MS. Spontaneous human lymphocyte mediated cytotoxicity against tumor target cells: IX. The quantitation of natural killer cell activity. J Clin Immunol. 1981;1:51. doi: 10.1007/BF00915477. [DOI] [PubMed] [Google Scholar]
  • 25.Relyveld EH, Bizzini B, Ophir R, Ben-Efraim S. Synergy between low-dose chemotherapy and immunotherapy in mouse L1210 leukemia. Cancer Treat Rep. 1987;71:241. [PubMed] [Google Scholar]
  • 26.Richner J, Cerny T, Joss RA, Micksche M, Brunner KW. Phase II study of continuous IFN a2b combined with CDDP in advanced malignant melanoma. Proc Am Assoc Clin Oncol. 1990;9:280. [Google Scholar]
  • 27.Schlaefli E, Ehrke MK, Mihich E. The effects of dichlorotrans-dihydroxy-bis-isopropyl-amine-platinum IV on the primary cell-mediated cytotoxic response. Immunopharmacology. 1983;6:107. doi: 10.1016/0162-3109(83)90004-8. [DOI] [PubMed] [Google Scholar]
  • 28.Silverman P, Creager RJ, Spitzer TR, et al. A phase II trial of cisplatin and interferon-alpha 2B in advanced malignant melanoma, breast carcinoma, and non-small cell lung carcinoma. Proc Am Assoc Clin Oncol. 1991;10:297. [Google Scholar]
  • 29.Turk JL, Parker D. Effect of cyclophosphamide on immunological control mechanisms. Immunol Rev. 1982;65:99. doi: 10.1111/j.1600-065x.1982.tb00429.x. [DOI] [PubMed] [Google Scholar]
  • 30.Xy Z-Y, Hosokawa M, Morikawa K, Hatekeyama M, Kobayashi H. Overcoming suppression of antitumor immune reactivity in tumor-bearing rats by treatment with bleomycin. Cancer Res. 1988;48:6658. [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES